Jianyou Co., Ltd. announced that its subsidiary Jianxin Pharmaceutical received a notice from the US FDA on October 20, 2026. The ANDA application for elibulin mesylate injection was approved, ANDA No. 218930. This product is suitable for patients with metastatic breast cancer who have previously been treated with at least two chemotherapy regimens, and patients with unresectable or metastatic liposarcoma who have previously received treatment regimens containing anthracyclines.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.